首页/数据集/Early Changes In B Cell Subsets Predict Risk Of Autoimmunity Following Combination Immune Checkpoint Blockade

Early Changes In B Cell Subsets Predict Risk Of Autoimmunity Following Combination Immune Checkpoint Blockade

NIAID Data Ecosystem2026-03-11 收录

免疫检查点阻断治疗

自身免疫性疾病风险

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104600 数据链接链接失效反馈

官方服务：

资源简介：

We report changes in B cells in patients treated with combination immune checkpoint blockade (CCB; anti-CTLA4 and anti-PD1) We examine CD19+ sorted B cells before and after CCB therapy

应用场景：

创建时间：

2019-05-15

乳腺癌与肺腺癌免疫预后

免疫检查点阻断治疗

Background: Constructed an immune-prognosis index (IPI) and divided lung adenocarcinoma (LUAD) patients into different subgroups according to IPI score, describe the molecular and immune characteristi

NIAID Data Ecosystem70

Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation

免疫检查点阻断治疗

肿瘤抗原呈递

One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machin

NIAID Data Ecosystem40

Table_1_Risk of Systemic Lupus Erythematosus in Patients With Anti-phospholipid Syndrome: A Population-Based Study.DOCX

自身免疫性疾病风险

风湿免疫流行病学

Objective: To investigate the association between anti-phospholipid syndrome (APS) and the risk of newly diagnosed systemic lupus erythematosus (SLE). Methods: We used 2003–2013 data derived from Taiw

NIAID Data Ecosystem10

Table_4_Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer.DOCX

胰腺癌免疫微环境

免疫检查点阻断治疗

Tumor microenvironment comprises of a variety of cell types, which is quite complex and involved in chemotherapy and immune checkpoint blockage resistance. In order to explore the mechanisms involved

NIAID Data Ecosystem40

DataSheet1_Reclassifying TNM stage I/II colorectal cancer into two subgroups with different overall survival, tumor microenvironment, and response to immune checkpoint blockade treatment.ZIP

结直肠癌免疫微环境

免疫检查点阻断治疗

Background: The traditional TNM staging system is often insufficient to differentiate the survival discrepancies of colorectal cancer (CRC) patients at TNM stage I/II. Our study aimed to reclassify st

NIAID Data Ecosystem10

Early Changes In B Cell Subsets Predict Risk Of Autoimmunity Following Combination Immune Checkpoint Blockade

资源简介：

相关数据集